Myriad Genetics Inc (MYGN) - Total Liabilities
Based on the latest financial reports, Myriad Genetics Inc (MYGN) has total liabilities worth $338.60 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Myriad Genetics Inc to assess how effectively this company generates cash.
Myriad Genetics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Myriad Genetics Inc's total liabilities have evolved over time, based on quarterly financial data. Check MYGN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Myriad Genetics Inc Competitors by Total Liabilities
The table below lists competitors of Myriad Genetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hey-Song Corp
TW:1234
|
Taiwan | NT$5.51 Billion |
|
Changshu Tongrun Auto
SHG:603201
|
China | CN¥1.31 Billion |
|
Guangxi Fenglin Wood Industry Group Co Ltd
SHG:601996
|
China | CN¥989.72 Million |
|
RDC Semiconductor Co Ltd
TWO:3228
|
Taiwan | NT$197.21 Million |
|
JMT Network Services Public Company Limited
BK:JMT
|
Thailand | ฿10.00 Billion |
|
Hangzhou Zongheng Commun
SHG:603602
|
China | CN¥1.45 Billion |
|
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
|
USA | $5.31 Million |
|
Aces Electronics Co Ltd
TW:3605
|
Taiwan | NT$6.76 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Myriad Genetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Myriad Genetics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Myriad Genetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Myriad Genetics Inc (1995–2025)
The table below shows the annual total liabilities of Myriad Genetics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $338.60 Million | +3.71% |
| 2024-12-31 | $326.50 Million | -10.13% |
| 2023-12-31 | $363.30 Million | +16.11% |
| 2022-12-31 | $312.90 Million | -11.33% |
| 2021-12-31 | $352.90 Million | -34.38% |
| 2020-12-31 | $537.80 Million | +13.51% |
| 2019-12-31 | $473.80 Million | +126.48% |
| 2018-12-31 | $209.20 Million | -53.16% |
| 2017-12-31 | $446.60 Million | +237.31% |
| 2016-12-31 | $132.40 Million | +27.19% |
| 2015-12-31 | $104.10 Million | -0.68% |
| 2014-12-31 | $104.82 Million | +39.33% |
| 2013-12-31 | $75.23 Million | +36.84% |
| 2012-12-31 | $54.98 Million | +24.84% |
| 2011-12-31 | $44.03 Million | +21.42% |
| 2010-12-31 | $36.27 Million | +12.62% |
| 2009-12-31 | $32.20 Million | -56.30% |
| 2008-12-31 | $73.69 Million | +132.42% |
| 2007-12-31 | $31.70 Million | +18.20% |
| 2006-12-31 | $26.82 Million | +15.19% |
| 2005-12-31 | $23.29 Million | +54.41% |
| 2004-12-31 | $15.08 Million | -22.01% |
| 2003-12-31 | $19.34 Million | -32.20% |
| 2002-12-31 | $28.52 Million | -12.47% |
| 2001-12-31 | $32.58 Million | +13.66% |
| 2000-12-31 | $28.67 Million | +430.90% |
| 1999-12-31 | $5.40 Million | -45.45% |
| 1998-12-31 | $9.90 Million | 0.00% |
| 1997-12-31 | $9.90 Million | +5.32% |
| 1995-12-31 | $9.40 Million | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more